{"id":1082,"date":"2008-11-01T12:04:00","date_gmt":"2008-11-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/fda-erneuert-die-warnung-vor-der-kombination-von-amiodaron-plus-simvastatin"},"modified":"2008-11-01T12:04:00","modified_gmt":"2008-11-01T11:04:00","slug":"fda-erneuert-die-warnung-vor-der-kombination-von-amiodaron-plus-simvastatin","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2008\/fda-erneuert-die-warnung-vor-der-kombination-von-amiodaron-plus-simvastatin","title":{"rendered":"FDA erneuert die Warnung vor der Kombination von Amiodaron plus Simvastatin"},"content":{"rendered":"<p>Im Juni 2007 haben wir \u00fcber UAW und Wechselwirkungen des Antiarrhythmikums Amiodaron berichtet (1). In einer \u201eInformation for Health Care Professionals\u201d vom 8. August 2008 erinnert die amerikanische Gesundheitsbeh\u00f6rde FDA an das erh\u00f6hte Risiko f\u00fcr Rhabdomyolyse mit konsekutivem Nierenversagen (und Tod) unter der Kombinationstherapie von Amiodaron plus Simvastatin (2). Das Risiko ist dosisabh\u00e4ngig und insbesondere [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Juni 2007 haben wir \u00fcber UAW und Wechselwirkungen des Antiarrhythmikums Amiodaron berichtet (1). In einer \u201eInformation for Health Care Professionals\u201d vom 8. August 2008 erinnert die amerikanische Gesundheitsbeh\u00f6rde FDA an das erh\u00f6hte Risiko f\u00fcr Rhabdomyolyse mit konsekutivem Nierenversagen (und Tod) unter der Kombinationstherapie von Amiodaron plus Simvastatin (2). Das Risiko ist dosisabh\u00e4ngig und insbesondere [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[127,126,1047,451,449,455,453,456,1050,506,505,443,1044],"class_list":["post-1082","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-amiodaron","tag-antiarrhythmika","tag-arzneimittelinteraktionen","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-lipidsenker","tag-myopathie","tag-rhabdomyolyse","tag-simvastatin","tag-statine","tag-wechselwirkungen"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1082"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1082\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}